Vandebroek Sophie V.'s Insider Trades & SAST Disclosures
Vandebroek Sophie V.'s most recent trade in Idexx Laboratories, Inc. was a trade of 344 Common Stock done at an average price of $420.4 . Disclosure was reported to the exchange on Nov. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Vandebroek Sophie V..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 420.44 per share. | 27 Nov 2024 | 344 | 905 (0%) | 0% | 420.4 | 144,630 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Nov 2024 | 224 | 1,249 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 609 | 609 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 262 | 262 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 257 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 257 | 1,473 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,218 | 2,676 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 977 | 1,458 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 245.79 per share. | 05 Mar 2024 | 1,404 | 2,620 (0%) | 0% | 245.8 | 345,089 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 1,404 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 562.98 per share. | 05 Mar 2024 | 1,404 | 1,216 (0%) | 0% | 563.0 | 790,427 | Common Stock |
| Revvity Inc. | Vandebroek V. Sophie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 264 | 481 (0%) | 0% | 0 | Common Stock | |
| Revvity Inc. | Vandebroek Sophie V. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 217 | 217 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 645 | 645 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 257 | 257 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 344 | 1,216 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 344 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 469.02 per share. | 04 May 2023 | 2,187 | 872 (0%) | 0% | 469.0 | 1,025,740 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 2,187 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.62 per share. | 04 May 2023 | 2,187 | 3,059 (0%) | 0% | 206.6 | 451,878 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 04 May 2023 | 500 | 8,173 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 945 | 945 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 344 | 568 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2022 | 224 | 344 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2022 | 224 | 872 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 723 | 723 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 224 | 224 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Sale of securities on an exchange or to another person at price $ 538.20 per share. | 12 Feb 2021 | 3,046 | 3,321 (0%) | 0% | 538.2 | 1,639,357 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 160.28 per share. | 12 Feb 2021 | 3,046 | 6,367 (0%) | 0% | 160.3 | 488,213 | Common Stock |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 3,046 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2020 | 1,279 | 1,279 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sophie V. Vandebroek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2020 | 370 | 3,741 | - | - | Deferred Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges